Technical Analysis for HRMY - Harmony Biosciences Holdings, Inc.
Grade | Last Price | % Change | Price Change |
---|---|---|---|
B | 38.78 | -1.47% | -0.58 |
HRMY closed down 1.47 percent on Thursday, February 6, 2025, on 84 percent of normal volume. The stock exhibited some range contraction during this trading session as price made an NR7 -- narrowest range of the last seven sessions.
Earnings due: Feb 20
*** please verify all earnings dates ***ADX | Long Term | Intermediate Term | Short Term |
---|---|---|---|
Weak or Absent | Up | Up | Flat |
Date | Alert Name | Type | % Chg |
---|---|---|---|
NR7 | Range Contraction | 0.00% | |
NR7-2 | Range Contraction | 0.00% | |
NR7 | Range Contraction | -1.47% | |
NR7-2 | Range Contraction | -1.47% | |
MACD Bearish Signal Line Cross | Bearish | -0.51% | |
NR7 | Range Contraction | -0.51% | |
Gapped Down | Weakness | 0.21% | |
NR7 | Range Contraction | -1.92% | |
Up 3 Days in a Row | Strength | -1.92% | |
Up 4 Days in a Row | Strength | -1.92% |
Alert | Time |
---|---|
10 DMA Support | about 10 hours ago |
Fell Below 10 DMA | about 10 hours ago |
Possible NR7 | about 10 hours ago |
60 Minute Opening Range Breakdown | about 11 hours ago |
Fell Below Previous Day's Low | about 11 hours ago |
Get a Trading Assistant
Let us help you stay on top of your investments. We will alert you to important technical developments on your
portfolio & watchlist.
- Earnings date: 02/20/2025
Harmony Biosciences Holdings, Inc., a commercial-stage pharmaceutical company, focuses on developing and commercializing therapies for patients living with rare neurological disorders. Its lead product includes WAKIX (pitolisant) for the treatment of pediatric patients suffering from narcolepsy. Harmony Biosciences Holdings, Inc. was formerly known as Harmony Biosciences II, Inc. and changed its name to Harmony Biosciences Holdings, Inc. in February 2020. The company was founded in 2017 and is based in Plymouth Meeting, Pennsylvania.
Sector: Healthcare
Industry: Biotechnology
Keywords: Pharmaceutical Neurological Disorders Stage Pharmaceutical Ethers Urological Disorders Chloroarenes Narcolepsy Piperidines Rare Neurological Disorders Stimulants
Classification
Sector: Healthcare
Industry: Biotechnology
Keywords: Pharmaceutical Neurological Disorders Stage Pharmaceutical Ethers Urological Disorders Chloroarenes Narcolepsy Piperidines Rare Neurological Disorders Stimulants
Indicator | Bull Case | Neutral / Hold | Bear Case |
---|---|---|---|
50 DMA | |||
200 DMA | |||
ADX Trend | |||
Oversold / Overbought | |||
Relative Strength |
Indicator | Value |
---|---|
52 Week High | 41.61 |
52 Week Low | 28.14 |
Average Volume | 539,604 |
200-Day Moving Average | 33.92 |
50-Day Moving Average | 35.66 |
20-Day Moving Average | 38.03 |
10-Day Moving Average | 38.76 |
Average True Range | 1.37 |
RSI (14) | 58.68 |
ADX | 24.32 |
+DI | 27.42 |
-DI | 18.47 |
Chandelier Exit (Long, 3 ATRs) | 36.83 |
Chandelier Exit (Short, 3 ATRs) | 37.26 |
Upper Bollinger Bands | 41.22 |
Lower Bollinger Band | 34.84 |
Percent B (%b) | 0.62 |
BandWidth | 16.78 |
MACD Line | 1.04 |
MACD Signal Line | 1.10 |
MACD Histogram | -0.0573 |
Pivot Point Level | Traditional / Classic | Fibonacci | Demark | Woodie | Camarilla |
---|---|---|---|---|---|
Resistance 4 (R4) | 40.19 | ||||
Resistance 3 (R3) | 40.30 | 39.93 | 39.96 | ||
Resistance 2 (R2) | 39.93 | 39.57 | 39.88 | 39.88 | |
Resistance 1 (R1) | 39.36 | 39.35 | 39.18 | 39.25 | 39.80 |
Pivot Point | 38.99 | 38.99 | 38.90 | 38.94 | 38.99 |
Support 1 (S1) | 38.42 | 38.63 | 38.24 | 38.31 | 37.76 |
Support 2 (S2) | 38.05 | 38.41 | 38.00 | 37.68 | |
Support 3 (S3) | 37.48 | 38.05 | 37.61 | ||
Support 4 (S4) | 37.37 |